Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial Prednisolone Weaning and Adrenal Suppression in Childhood Nephrotic Syndrome
ACTRN12621001428853Phase 3Terminated
- Sponsor
- Dr Amelia Le Page
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of prednisolone in Idiopathic nephrotic syndrome (INS) (2 arms), sponsored by Dr Amelia Le Page. Primary endpoint: Frequency of adrenal suppression in the whole cohort. Started Jan 2022; status: terminated.
02
Drugs
prednisolone
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on ACTRN12621001428853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001428853.